Department of Epidemiology and Public Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Ann Acad Med Singap. 2010 Feb;39(2):129-35.
This study evaluates determinants, expectations, association with quality of life (QOL) and doctor's awareness of Complementary and Alternative Medicine (CAM) use in Singapore cancer patients.
We interviewed 316 patients visiting the Cancer Centre of the National University Hospital on behaviour, attitudes and expectations towards CAM and assessed QOL via Euroqol Questionnaire (EQ-5D). Medical information was obtained from oncologists.
One hundred and seventy-three patients (55%) reported CAM use after cancer diagnosis. Chinese ethnicity, tertiary education, age <65 years and previous CAM use were independent predictors of CAM use. Fifty-one per cent of CAM users informed their doctors about their use and 15% of doctors reported to be aware of CAM use in these patients. Thirty-seven per cent believed CAM to be equally or more effective than conventional cancer therapies and 78% expected at least basic knowledge about CAM from their oncologists. Twenty-fi ve per cent of patients reported concurrent use of oral CAM and chemotherapy, of which oncologists were unaware in 86% of cases. CAM users had higher EuroQol utility scores than non-CAM users (0.79 versus 0.73, respectively, P = 0.03), in particularly those aged >or=65 years and those with stage IV disease.
Singapore cancer patients show high prevalence of CAM use, high expectations regarding its effectiveness and doctors' knowledge on CAM and many use it concurrently with chemotherapy or radiotherapy. Since oncologists are generally unaware of CAM use in their patients, doctor-patient communication on CAM use needs to be improved. The association of CAM use and higher QOL scores in some subgroups deserves further exploration.
本研究评估了新加坡癌症患者使用补充和替代医学(CAM)的决定因素、期望、与生活质量(QOL)的关联以及医生对其的认知。
我们采访了 316 名在国立大学医院癌症中心就诊的患者,了解他们对 CAM 的行为、态度和期望,并通过欧洲五维健康量表(EQ-5D)评估 QOL。从肿瘤医生那里获取医疗信息。
173 名患者(55%)在癌症确诊后报告使用了 CAM。华人种族、高等教育、年龄<65 岁和以前使用过 CAM 是使用 CAM 的独立预测因素。51%的 CAM 用户将其使用情况告知了医生,15%的医生报告称了解这些患者的 CAM 使用情况。37%的患者认为 CAM 与传统癌症治疗同样有效或更有效,78%的患者期望他们的肿瘤医生至少对 CAM 有基本的了解。25%的患者报告同时使用口服 CAM 和化疗,其中 86%的病例肿瘤医生并不知情。CAM 用户的 EuroQol 效用评分高于非 CAM 用户(分别为 0.79 和 0.73,P=0.03),特别是年龄≥65 岁和疾病处于 IV 期的患者。
新加坡癌症患者 CAM 的使用率较高,对其疗效的期望较高,且医生对 CAM 的了解程度较高,许多患者同时使用 CAM 与化疗或放疗。由于肿瘤医生通常不知道他们的患者正在使用 CAM,因此需要改进医患之间关于 CAM 使用的沟通。CAM 使用与某些亚组更高的 QOL 评分之间的关联值得进一步探讨。